BEACON: A Phase II, Patient-blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy
Latest Information Update: 07 May 2024
At a glance
- Drugs Mometasone (Primary)
- Indications Rhinosinusitis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Acronyms BEACON
- Sponsors Lyra Therapeutics
- 30 Apr 2024 According to a Lyra Therapeutics media release, an end-of-Phase 2 meeting for LYR-220 with the FDA is anticipated in the second half of 2024.
- 30 Apr 2024 According to a Lyra Therapeutics media release, company plans to present additional secondary endpoint data from the BEACON Phase 2 clinical trial of LYR-220 at the 2024 Combined Otolaryngology Spring Meetings (COSM) being held May 15-19, 2024 in Chicago, IL.
- 18 Sep 2023 Status changed from active, no longer recruiting to completed.